Abstract
Introduction: The main objective of this study was to evaluate the impact of hemoadsorption on the elimination of inflammatory mediators. Methods: A prospective, bicenter, observational cohort study was conducted between March 2020 and February 2022 to explore the immunomodulatory response, demographic and clinical characteristics of individuals with COVID-19 admitted to the ICU with severe acute respiratory failure and in need of CRRT with Oxiris® with or without AKI. Results: Sixty-four patients were analyzed. Statistically significant differences were observed between exposed and unexposed groups, in relation to the reduction in D-dimer levels −15,614 (24,848.9) versus −4,136.5 (9,913.47) (p 0.031, d: 1.59, 95% CI: −21,830, −1,126). An increase in PCT was observed 0.47 (2.08) versus −0.75 (2.3) (p 0.044 95% CI: 0.03, 2.44). No differences were found in a decrease in CRP −4.21 (7.29) versus −1.6 (9.02) (p 0.22) nor in the rest of inflammatory parameters fibrinogen, IL-6, ferritin, lymphocytes, and neutrophils. Subgroup analysis in patients exposed to therapy also showed a significant decrease in D-dimer of 55% from baseline: 6,000 (1,984.5–27,750) pre-therapy versus 2,700 (2,119.5–6,145) (95% CI: −23,000, −2,489) post-therapy with a strong effect size (p 0.001, d: 0.65). Conclusion: The hemoadsorptive therapy in COVID-19 was associated with a significant decrease in D-dimer parameters without showing decreases in the rest of the clinical, inflammatory parameters and severity scales analyzed.
Journal Section:
Hemodialysis – Research Article
References
1.
Lau
SKP
, Lau
CCY
, Chan
KH
, Li
CPY
, Chen
H
, Jin
DY
, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment
. J Gen Virol
. 2013
;94
(Pt 12
):2679
–90
. 2.
Remy
KE
, Mazer
M
, Striker
DA
, Ellebedy
AH
, Walton
AH
, Unsinger
J
, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections
. JCI Insight
. 2020
;5
(17
):e140329
. 3.
Ronco
C
, Reis
T
. Kidney involvement in COVID-19 and rationale for extracorporeal therapies
. Nat Rev Nephrol
. 2020
;16
(6
):308
–10
. 4.
Kooman
JP
, van der Sande
FM
. COVID-19 in ESRD and acute kidney injury
. Blood Purif
. 2021
;50
(4–5
):610
–20
. 5.
Lan
SH
, Lai
CC
, Huang
HT
, Chang
SP
, Lu
LC
, Hsueh
PR
. Tocilizumab for severe COVID-19: a systematic review and meta-analysis
. Int J Antimicrob Agents
. 2020
;56
(3
):106103
. 6.
7.
Zhang
H
, Zhu
G
, Yan
L
, Lu
Y
, Fang
Q
, Shao
F
. The absorbing filter Oxiris in severe coronavirus disease 2019 patients: a case series
. Artif Organs
. 2020
;44
(12
):1296
–302
. 8.
Cascarano
L
, Cutuli
SL
, Pintaudi
G
, Tanzarella
ES
, Carelli
S
, Anzellotti
G
, et al. Extracorporeal immune modulation in COVID-19 induced immune dysfunction and secondary infections: the role of oXiris® membrane
. Minerva Anestesiol
. 2021
;87
(3
):384
–5
. 9.
Napp
LC
, Bauersachs
J
. Extracorporeal hemoadsorption: an option for COVID-19-associated cytokine storm syndrome
. Shock
. 2020
;54
(5
):700
–1
. 10.
Liu
Y
, Chen
X
, Wang
D
, Li
H
, Huang
J
, Zhang
Z
, et al. Hemofiltration successfully eliminates severe cytokine release syndrome following CD19 CAR-T-cell therapy
. J Immunother
. 2018
;41
(9
):406
–10
. 11.
Peng
ZY
, Carter
MJ
, Kellum
JA
. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats
. Crit Care Med
. 2008
;36
(5
):1573
–7
. 12.
Cecchi
M
, Ulsamer
A
, Villa
G
. Oxiris membrane in sepsis and multiple organ failure
. Contrib Nephrol
. 2023
;200
:55
–65
. 13.
Bernardi
MH
, Rinoesl
H
, Dragosits
K
, Ristl
R
, Hoffelner
F
, Opfermann
P
, et al. Effect of hemoadsorption during cardiopulmonary bypass surgery: a blinded, randomized, controlled pilot study using a novel adsorbent
. Crit Care
. 2016
;20
:96
. 14.
Malard
B
, Lambert
C
, Kellum
JA
. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
. Intensive Care Med Exp
. 2018
;6
(1
):12
. 15.
Zang
S
, Chen
Q
, Zhang
Y
, Xu
L
, Chen
J
. Comparison of the clinical effectiveness of AN69-oXiris versus AN69-ST filter in septic patients: a single-centre study
. Blood Purif
. 2022
;51
(7
):617
–29
. 16.
Ronco
C
, Bagshaw
SM
, Bellomo
R
, Clark
WR
, Husain-Syed
F
, Kellum
JA
, et al. Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation
. Blood Purif
. 2021
;50
(1
):17
–27
. 17.
Villa
G
, Romagnoli
S
, De Rosa
S
, Greco
M
, Resta
M
, Pomarè Montin
D
, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study
. Crit Care
. 2020
;24
(1
):605
. 18.
Alharthy
A
, Faqihi
F
, Memish
ZA
, Balhamar
A
, Nasim
N
, Shahzad
A
, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series
. Artif Organs
. 2021
;45
(5
):E101
–12
. 19.
Melegari
G
, Bertellini
E
, Melegari
A
, Trenti
T
, Malaguti
S
, Barbieri
A
. Hemoadsorption cartridge and coronavirus disease 2019 infections: a case report and brief literature review
. Artif Organs
. 2021
;45
(5
):E130
–5
. 20.
FDA approval document
. Available from: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations21.
Berlot
G
, Pintacuda
S
, Moro
E
, Paluzzano
G
, Scamperle
A
, Chillemi
A
, et al. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: preliminary results
. Int J Artif Organs
. 2022
;45
(1
):75
–80
. 22.
De Epidemiología
S
. INFORME EPIDEMIOLÓGICO VIGILANCIA DE COVID-19 INFECCIÓN POR SARS-CoV-2 Red de Vigilancia Epidemiológica SEMANA 37 Martes, 20 de septiembre de
. 2022
.23.
Herrera Gutierrez
ME
, Leoz Abellanas
G
, Maynar Moliner
J
, Sanchez-Izquierdo Riera
JA
. Protocolo del uso del citrato en depuración extracorpórea continua (TCDE)
. 2019
; p. 1
–49
.24.
STROBE Statement-checklist of items that should be included in reports of observational studies
[Internet]. Available from: http://www.epidem.com/25.
Zhang
H
, Zhu
G
, Yan
L
, Lu
Y
, Fang
Q
, Shao
F
. The absorbing filter Oxiris in severe coronavirus disease 2019 patients: a case series
. Artif Organs
. 2020
;44
(12
):1296
–302
. 26.
Nassiri
AA
, Hakemi
MS
, Miri
MM
, Shahrami
R
, Koomleh
AA
, Sabaghian
T
. Blood purification with CytoSorb in critically ill COVID-19 patients: a case series of 26 patients
. Artif Organs
. 2021
;45
(11
):1338
–47
. 27.
Premužić
V
, Babel
J
, Gardijan
D
, Lapić
I
, Gabelica
R
, Ostojić
Z
, et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients
. Ther Apher Dial
. 2022
;26
(2
):316
–29
. 28.
González-Fernández
M
, Quílez-Trasobares
N
, Barea-Mendoza
JA
, Molina-Collado
Z
, Arias-Verdú
D
, Barrueco-Francioni
J
, et al. Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient
. Sci Rep
. 2023
;13
(1
):6479
. 29.
Rhodes
A
, Evans
LE
, Alhazzani
W
, Levy
MM
, Antonelli
M
, Ferrer
R
, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock
. Intensive Care Med
. 2017
;43
(3
):304
–77
. 30.
Schädler
D
, Pausch
C
, Heise
D
, Meier-Hellmann
A
, Brederlau
J
, Weiler
N
, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial
. PLoS One
. 2017
;12
(10
):e0187015
. 31.
Kellum
JA
, Song
M
, Venkataraman
R
. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia
. Crit Care Med
. 2004
;32
(3
):801
–5
. 32.
Friesecke
S
, Träger
K
, Schittek
GA
, Molnar
Z
, Bach
F
, Kogelmann
K
, et al. International registry on the use of the CytoSorb® adsorber in ICU patients: study protocol and preliminary results
. Med Klin Intensivmed Notfmed
. 2019
;114
(8
):699
–707
. 33.
Villa
G
, Romagnoli
S
, De Rosa
S
, Greco
M
, Resta
M
, Pomarè Montin
D
, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study
. Crit Care
. 2020
;24
(1
):605
. 34.
Naymagon
L
, Zubizarreta
N
, Feld
J
, van Gerwen
M
, Alsen
M
, Thibaud
S
, et al. Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
. Thromb Res
. 2020
;196
:99
–105
. 35.
Rostami
M
, Mansouritorghabeh
H
. D-dimer level in COVID-19 infection: a systematic review
. Expert Rev Hematol
. 2020
;13
(11
):1265
–75
. 36.
Li
Y
, Deng
Y
, Ye
L
, Sun
H
, Du
S
, Huang
H
, et al. Clinical significance of plasma D-dimer in COVID-19 mortality
. Front Med
. 2021
;8
:638097
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
